Top entities: Autonomix Medical, War, Inc., United States, United States — United States Securities and Exchange Commission.

What category does this event fall under?

Tech — classified as patent issuance.

What is the sentiment of coverage?

Aggregate sentiment score: 10 on a -100 to +100 scale (negative = critical coverage, positive = favorable coverage).

What were the key actions taken?

Autonomix Medical issued patent · Autonomix Medical issued patent

Is this event still developing?

This is an active story, last updated Aug 04, 2026. Coverage continues to evolve.

Tech patent issuance

Autonomix Medical Secures Two New Patents

Q: When did this event occur?

First reported Jul 23, 2026; last updated Aug 04, 2026.

Q: What is the market impact?

General. The issuance of these patents strengthens Autonomix Medical's intellectual property portfolio, potentially enhancing its competitive position and long-term value.

Analysis based on 8 articles · First reported Jul 23, 2026 · Last updated Aug 04, 2026

Sentiment

Attention

Articles

Market Impact

General

Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard

Market Impact

The issuance of these patents strengthens Autonomix Medical's intellectual property portfolio, potentially enhancing its competitive position and long-term value. However, as the technology is still investigational and not yet commercialized, the immediate market impact is limited, with the news likely providing a modest positive sentiment for the company's stock.

Medical Devices Biotechnology

Event Summary

Autonomix Medical, Inc. (NASDAQ: AMIX), a medical device company focused on precision nerve-targeted treatments, announced the issuance of two new U.S. patents in July and August 2026. On July 23, 2026, the company received U.S. Patent No. 12,471,776 titled 'ANS Assessment Systems, Kits, and Methods,' which covers systems and methods for monitoring physiologic signals to assess autonomic nervous system activity. On August 4, 2026, the company received U.S. Patent No. 12,433,670 titled 'Systems and Methods for Treating Cancer and/or Augmenting Organ Function,' which expands protection for technologies that sense, map, and selectively target nerves associated with tumors and cancer-related pain. These patents strengthen Autonomix's intellectual property portfolio and support its platform for treating conditions such as pancreatic cancer pain and other autonomic nervous system disorders. The company's technology is investigational and not yet cleared for marketing in the United States.

Key Actions

80 Autonomix Medical issued patent

Entities Involved

stock

Autonomix Medical

Autonomix Medical is the central entity, receiving two new patents that expand its IP portfolio and support its precision neuromodulation platform. This strengthens its position in the medical device space, though the technology remains investigational.

Importance 100.0 Sentiment 20.0

per

War, Inc.

War, Inc., CEO of Autonomix Medical, is quoted in the announcements, highlighting the strategic value of the patents. His leadership is important for the company's direction, but the patents themselves are the primary focus.

Importance 30.0 Sentiment 10.0

cnt

United States

The patents were issued by the United States Patent and Trademark Office, providing legal protection within the U.S. This is relevant for Autonomix's operations, but the event does not significantly impact the country as a whole.

Importance 20.0 Sentiment 0.0

govactor

United States — United States Securities and Exchange Commission

The United States — United States Securities and Exchange Commission is mentioned in the forward-looking statements as the regulator for Autonomix's filings. This is a routine reference and does not play a direct role in the patent issuance.

Importance 10.0 Sentiment 0.0

Relationships

United States related ↔ United States — United States Securities and Exchange Commission

ERGEN INTELLIGENCE

Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard